16-30 of 878
Optimizing Treatment Intensity in Early-Stage TNBC
Project Oncology®Optimizing Treatment Intensity in Early-Stage TNBC
Roberto Leon-Ferre, MD
Emerging TNBC Research: Biomarkers, Genomics, and Adaptive Treatment
Project Oncology®Emerging TNBC Research: Biomarkers, Genomics, and Adaptive Treatment
Roberto Leon-Ferre, MD
Implementing Lifestyle Medicine in Breast Cancer Survivorship Care
Project Oncology®Implementing Lifestyle Medicine in Breast Cancer Survivorship Care
Amy Comander, MD
Matching TNBC Treatment Intensity to Patient Needs
Project Oncology®Matching TNBC Treatment Intensity to Patient Needs
Roberto Leon-Ferre, MD
Breast Cancer Survivorship: Why Lifestyle Medicine Matters
Project Oncology®Breast Cancer Survivorship: Why Lifestyle Medicine Matters
Amy Comander, MD
DPYD Testing Before Fluoropyrimidine Therapy: Benefits, Risks, and Guidance
Project Oncology®DPYD Testing Before Fluoropyrimidine Therapy: Benefits, Risks, and Guidance
Daniel Hertz, PhD, PharmD
- advertisement
Communicating Pathologic Response Results in Resectable NSCLC
Project Oncology®Communicating Pathologic Response Results in Resectable NSCLC
Charles Turck, PharmD, BCPS, BCCCP
Alexander Spira, MD, PhD, FACP
Robert Merritt, MD
Optimizing First-Line Care for PD-L1–Low Metastatic NSCLC
Project Oncology®Optimizing First-Line Care for PD-L1–Low Metastatic NSCLC
Charles Turck, PharmD, BCPS, BCCCP
Deepa Rangachari, MD
Managing Immune-Related Adverse Events in Metastatic NSCLC
Project Oncology®Managing Immune-Related Adverse Events in Metastatic NSCLC
Charles Turck, PharmD, BCPS, BCCCP
Paul Bunn, MD
Managing High-Risk Subgroups in Metastatic NSCLC
Project Oncology®Managing High-Risk Subgroups in Metastatic NSCLC
Charles Turck, PharmD, BCPS, BCCCP
Melina Marmarelis, MD
Deepa Rangachari, MD
How KIT D816V Shapes Systemic Mastocytosis Diagnosis and Treatment
Clinician's RoundtableHow KIT D816V Shapes Systemic Mastocytosis Diagnosis and Treatment
Brian P. McDonough, MD, FAAFP
Thanai Pongdee, MD
Survival Outcomes in Squamous Cell Carcinoma of the Anal Canal: POD1UM-303 Data
Project Oncology®Survival Outcomes in Squamous Cell Carcinoma of the Anal Canal: POD1UM-303 Data
Brian P. McDonough, MD, FAAFP
Stacey Cohen, MD
- advertisement
Optimizing cGVHD Treatment Decisions in the Second- and Third-Line Settings
Project Oncology®Optimizing cGVHD Treatment Decisions in the Second- and Third-Line Settings
Charles Turck, PharmD, BCPS, BCCCP
Stephanie Gregory, CNP
Real-World Strategies for Complex cGVHD Treatment Decisions
Project Oncology®Real-World Strategies for Complex cGVHD Treatment Decisions
Brian P. McDonough, MD, FAAFP
Doris M. Ponce, MD, MS
Interpreting Perioperative Trial Designs in Resectable NSCLC Research
Project Oncology®Interpreting Perioperative Trial Designs in Resectable NSCLC Research
Charles Turck, PharmD, BCPS, BCCCP
Laura Alder, MD
Christine Bestvina, MD
